



## BRAIN DISEASE SITE COMMITTEE MEETING AGENDA

Chelsea Hotel, Toronto, ON

Room: Carlyle

Saturday, May 4, 2019, 9:00 am – 12:00 pm

Chair : Dr. Warren Mason

Senior Investigator: Dr Chris O'Callaghan

### **CME Credits:**

*Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.*

### **Learning Objectives:**

1. To cite and analyze recent results of clinical studies conducted by or in collaboration with the Canadian Cancer Trials Group relevant to CNS malignancies
2. To summarize recent developments in molecular biology and therapeutics research, as related to CNS malignancies
3. To interpret and address, through clinical and translational research, the disease burden associated with CNS malignancies in Canada.
4. To interpret and apply new clinical trial methodologies in the field of clinical research in CNS malignancies

9:00 am **Welcome and Introductions**

9:05 am **CCTG Rare Cancer Initiative – Implications for Brain Disease Site – Dr. W. Mason/Dr. C. O'Callaghan**

### **Actively Accruing, Completed or Closed Trials**

9:15 am **CEC.1 (EORTC 26053\_22054/RTOG 0834) \*closed\***: Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in non-1p/19q Deleted Anaplastic Glioma – **Dr. W. Mason**

**CEC.5 (ALLIANCE 221208) \*closed\***: Randomized Phase II Study: Corticosteroids + Bevacizumab vs Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases – **Dr. W. Mason**

**CEC.6 (NCCTG N0577)**: Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy

with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma – **Dr. W. Mason/Dr. G. Cairncross**

**CEC.3 (NCCTG N107C) \*closed\***: A phase III trial of post-surgical stereotactic radiosurgery compared with whole brain radiotherapy (WBRT) for resected metastatic brain disease – **Dr. D. Roberge**

**IND.222 \*closed\***: A phase I/II trial of AZD2014 with temozolomide in patients with GBM at first progression – **Dr. W. Mason**

### **Guest Presentation**

9:30 am Imaging and Radiation Oncology Core (IROC) Cooperative QA Center – **Dr. J. Lowenstein**

10:00 am Refreshment Break

### **Newly Approved/Opened CCTG Trials**

10:30 am **CE.7 \*accrual suspended pending new amendment\***: A Phase III Trial of Stereotactic Radiosurgery compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases - **Dr. D. Roberge**

10:45 am **CE.8**: A phase III trial of the pan-proteasome inhibitor Marizomib with Radiotherapy and Temozolomide for newly-diagnosed GBM – **Dr. W. Mason**

### **Proposals for Discussion**

11:15 am **A071801**: A phase III trial of post-surgical single fraction stereotactic radiosurgery (SRS) compared with fractionated SRS for resected metastatic brain disease – **Dr. J. Greenspoon**

11:30 am **Concept**: A randomized trial of WBRT compared with targeted radiation treatment for patients with poor prognosis – **Dr. A. Nichol**

11:45 am Report from IND Committee - **Dr. M. Pitz**

12:00 pm Adjourn